The global peptide synthesis service market is expected to reach USD 1.7 billion in 2022 anticipated to grow at a CAGR of 13.6% during the forecast period 2022-2035.

The increasing prominence of biologics has spurred a notable pivot among pharmaceutical enterprises towards more sophisticated interventions such as peptide therapeutics. Since the discovery of insulin, the market for peptide-based drugs has flourished, encompassing over 80 medications that target a spectrum of ailments including cancer, diabetes, and HIV. Since 2017, the FDA has approved over 10 peptide drugs, including LupkynisTM and Zegalogue? in 2021, and ImcivreeTM, Victoza?, and LUPRON DEPOT? in 2020. A vast array of clinical trials, exceeding 1,000, is currently investigating the therapeutic potential of novel peptides.
The surging demand for these drugs emanates from their specificity, minimal drug interactions, diverse biological actions, prolonged half-lives, established pharmacological efficacy, and safety profiles. However, the synthesis and purification of peptides present challenges that impact both yield and purity. To counter this, numerous entities involved in peptide synthesis opt to engage contract manufacturers. Presently, more than 60 Contract Manufacturing Organizations (CMOs) and Contract Development and Manufacturing Organizations (CDMOs) offer services encompassing peptide development, manufacturing, and purification, consolidating themselves as comprehensive solutions for developers.
With continuous technological innovations, advancements in purification techniques, and an expanding pipeline, the peptide market is anticipated to undergo sustained growth. As pharmaceutical companies resume full operational capacities post-COVID-19, there is a projected uptick in demand for large-scale manufacturing of peptide therapeutics. Notably, the development of peptide-based COVID-19 vaccines will further amplify the need for manufacturing service providers to scale up production post-approval, addressing global demands.

Report Coverage
? The key insights from our research on the peptide contract manufacturing market, offering a high-level overview of its current status and expected evolution in the short, mid, and long term
? Introduction to peptides, discussing different classes, synthesis methods, modifications, purification strategies, applications, and the rationale behind outsourcing peptide manufacturing operations.
? Detailed insights into the regulatory landscape of peptide contract manufacturers across various regions like the US, Europe, Australia, China, India, Japan, and South Korea, including challenges faced due to regulatory scrutiny.
? An overview of companies providing peptide contract manufacturing services, highlighting parameters such as establishment year, company size, geographical locations, synthesis methods, purification techniques, and regulatory certifications.
? An analysis of prominent peptide contract manufacturers’ competitiveness based on service strength, manufacturing capabilities, facility numbers, synthesis, purification methods, and peptide modification
? Detailed profiles of key players in the peptide contract manufacturing domain, featuring company overviews, establishment years, employee count, headquarters, services offered, recent developments, and future outlooks.
? An analysis of recent developments in the peptide contract manufacturing industry, including partnerships, collaborations, and facility expansions between 2016 and 2021.
? In-depth analysis of completed, ongoing, and planned clinical studies on peptide therapeutics, focusing on trial parameters, industry players, study focus, and geographical regions.
? Analysis of peptide contract manufacturing service providers’ capabilities across different regions based on various parameters like CMO numbers, clinical sites, trials, patients enrolled, product types, and demand.
An analysis of the commercial and clinical demand for peptide therapeutics based on patient population, dosing frequency, and strength.
? Analysis of the overall peptide manufacturing capacity across different-sized companies, operational scales (clinical vs. commercial), and geographical regions.
? Potential strategic partners identified for collaboration with peptide therapeutics developers based on pipeline strength, maturity, establishment year, and company size.
? Qualitative analysis outlining factors for peptide drug developers to consider while deciding between in-house manufacturing or engaging a CMO’s services.
? Detailed analysis of the total cost of ownership for a peptide contract manufacturing service provider over ten years, considering direct and indirect expenses.
? Market forecast analysis projecting the peptide contract manufacturing market’s growth till 2035, segmented by operational scale, synthesis methods, company size, and geographical regions.
? Insightful discussion on how the COVID-19 pandemic might impact the peptide contract manufacturing market and initiatives taken by service providers to address pandemic-induced challenges.
? In-depth discussion on industry trends, drivers, challenges, and SWOT analysis, evaluating their impact on the evolution of the peptide contract manufacturing field.
? A summary of the entire report, presenting key takeaways, independent opinions on the peptide CMO market, upcoming trends influencing market growth, and insights from the research and analysis.
? Insights from a comprehensive survey involving multiple stakeholders in the peptide therapeutics contract manufacturing market.

Key Market Companies
? AmbioPharm
? CPC Scientific
? Creative Peptides
? CSBio
? Bachem
? BCN Peptide
? Corden Pharma
? PolyPeptide
? Senn Chemicals
? Auspep
? Chinese Peptide
? Hybio Pharmaceutical
? Peptide Institute
? ScinoPharm